(6-methoxy-1-oxo-3,4-dihydro-1H-2-thia-9-azafluoren-9-yl)acetic acid | 1161933-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (6-methoxy-1-oxo-3,4-dihydro-1H-2-thia-9-azafluoren-9-yl)acetic acid
• 英文别名: 2-(6-Methoxy-1-oxo-3,4-dihydrothiopyrano[3,4-b]indol-9-yl)acetic acid
• CAS: 1161933-29-4
• 化学式: C₁₄H₁₃NO₄S
• 分子量: 291.328
• InChiKey: FCVUKGXXILHEJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4,9-Dihydro-6-methoxy-pyrano<3,4-b>indol-1(3H)-on 在 劳森试剂 、 三甲基氯硅烷 、 sodium hydride 、 sodium iodide 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 48.0h， 生成 (6-methoxy-1-oxo-3,4-dihydro-1H-2-thia-9-azafluoren-9-yl)acetic acid
  参考文献：
  名称：

  Synthesis and Evaluations of GLP-1 Secretion and Anti-Diabetic Effect in KKAy Mice of New Tricyclic Compounds

  摘要：

  Glucagon-like peptide-1 (GLP-1), which belongs to the family of incretins, plays important role for the regulation of plasma glucose. Accordingly, GLP-1-based therapies for type 2 diabetes have recognized as one of the most interesting target. In this study, we have found the new tricyclic compounds having strong GLP-1 secretion from human intestinal L cells, and anti-diabetic properties in spontaneously obese and diabetic KKAy mice. The most potent compound 5ka was obtained as the unexpected product, and we would like to report the details of the synthesis, structure elucidations, pharmacological activities on secretion of GLP-1, and anti-diabetic effects using diabetic KKAy mice.

  DOI：

  10.3987/com-14-s(k)29

文献信息

• FUSED TRICYCLIC COMPOUND HAVING ALDOSE REDUCTASE INHIBITORY ACTIVITY
  申请人：TOYOOKA Naoki

  公开号：US20100145052A1

  公开（公告）日：2010-06-10

  A fused tricyclic compound having aldose reductase inhibitory activity and shown by the following formula, wherein R 1 represents 1 to 3 atoms or substituents selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl, cycloalkyl, alkylene, or alkoxy group, and a protected or unprotected hydroxyl or carboxyl group, R 2 represents a protected or unprotected carboxyl group, R 3 represents 1 or 2 atoms or substituents selected from a hydrogen atom, a halogen atom, an oxo group, a substituted or unsubstituted alkyl or alkoxy group, and a protected or unprotected carboxyl group, A represents an alkylene group, and B represents an oxygen atom, a sulfur atom, or a group shown by the following formula, wherein R 4 represents an alkyl or aryl group substituted by an aryl, cycloalkyl, or heterocyclic group, and X represents an oxygen atom or a sulfur atom, provided that, when B represents a group shown by the following formula: wherein R 4 represents an alkyl or aryl group substituted with an aryl, cycloalkyl, or heterocyclic group, X represents a sulfur atom.

  具有醛还原酶抑制活性的熔合三环化合物，其化学式如下：其中，R1代表1至3个原子或取代或未取代的烷基，环烷基，烷基，或烷氧基，以及受保护或未受保护的羟基或羧基中的一个或多个，或氢原子或卤素原子；R2代表受保护或未受保护的羧基；R3代表1或2个原子或取代或未取代的烷基，烷氧基，卤素原子，氧代基，或受保护或未受保护的羧基中的一个或多个，或氢原子；A代表烷基；B代表氧原子，硫原子，或由以下化学式表示的基团：其中，R4代表取代有芳基，环烷基，或杂环基团的烷基或芳基基团，X代表氧原子或硫原子，但当B代表由以下化学式表示的基团时：其中，R4代表取代有芳基，环烷基，或杂环基团的烷基或芳基基团，X代表硫原子。
• US8198447B2
  申请人：——

  公开号：US8198447B2

  公开（公告）日：2012-06-12
• Synthesis and Evaluations of GLP-1 Secretion and Anti-Diabetic Effect in KKAy Mice of New Tricyclic Compounds
  作者：Naoki Toyooka、Isao Adachi、Daisuke Minehira、Daisuke Takeda、Shota Miyawaki、Atsushi Kato、Akira Miyazaki、Ryuta Miyatake、Masahito Umezaki、Kyoko Miura、Yoshiro Kitahara、Kenji Sugimoto、Yuji Matsuya

  DOI：10.3987/com-14-s(k)29

  日期：——

  Glucagon-like peptide-1 (GLP-1), which belongs to the family of incretins, plays important role for the regulation of plasma glucose. Accordingly, GLP-1-based therapies for type 2 diabetes have recognized as one of the most interesting target. In this study, we have found the new tricyclic compounds having strong GLP-1 secretion from human intestinal L cells, and anti-diabetic properties in spontaneously obese and diabetic KKAy mice. The most potent compound 5ka was obtained as the unexpected product, and we would like to report the details of the synthesis, structure elucidations, pharmacological activities on secretion of GLP-1, and anti-diabetic effects using diabetic KKAy mice.